Navigation Links
HYCOR Broadens Diagnostic Offerings, Announces Agreements to License Biomarkers for Celiac Disease and Rheumatoid Arthritis
Date:7/26/2011

GARDEN GROVE, Calif., July 26, 2011 /PRNewswire/ -- HYCOR Biomedical, Inc., a leading manufacturer and marketer of in vitro diagnostic products, today announced that it has signed an agreement with Eurospital—a manufacturer of pharmaceutical products, medical-surgical and diagnostic devices—to license its tTG biomarker in all countries covered by the patent (excluding the US and Canada) for its ability to diagnose celiac disease. HYCOR today also announced that it has signed an agreement with AXIS-SHIELD—a developer of in vitro diagnostic tests—to license its anti-CCP biomarker for its ability to diagnose rheumatoid arthritis (RA). Customers will have access to these critical biomarkers from HYCOR in the coming weeks.

"We are pleased to offer HYCOR customers a tool to help clinicians diagnose these devastating, chronic diseases," said Dick Aderman, CEO, HYCOR. "We look forward to continuing to expand our diagnostic offerings, ensuring customers are able to meet the ever-changing needs of the healthcare professionals they serve."

Celiac disease is a condition that damages the lining of the small intestine and prevents it from absorbing nutrients properly, leading to malnutrition. The symptoms of celiac disease vary from one patient to the next, which poses challenges to healthcare professionals in the accurate diagnosis of the disease. If left untreated celiac disease can cause other complications, including autoimmune disease, anemia and hypoglycemia, and, in some instances, certain types of intestinal cancer.(i)

RA is a chronic autoimmune disease that leads to joint inflammation, as well as inflammation of the surrounding tissue. Early diagnosis of the disease, and early aggressive treatment, can delay joint destruction and prevent symptoms from worsening.(ii)

About HYCOR Biomedical, Inc.

Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.hycorbiomedical.com.

About Eurospital

Founded in 1948, Eurospital is a scientific organization active in such sectors as diagnostics, pharmaceutical industry and hospital practice. The Company is located in Trieste (ITALY), a city hosting a number of international research centers, which are now gaining increasing scientific importance in the field of biotechnology. The company is focused on the diagnosis of celiac diseases, gastroenterology, infectious diseases, septic infections.

About AXIS-SHIELD

Axis-Shield (www.axis-shield.com) is an international and innovative in vitro diagnostics company, headquartered in Dundee with R&D and manufacturing bases in Dundee and Oslo. The Group specializes in the supply of instruments and tests for the rapidly growing physician's office testing market and the development, manufacture and marketing of innovative proprietary diagnostics kits in areas of clinical need, including cardiovascular and neurological diseases, rheumatoid arthritis, and diabetes.

(i) PubMed Health, available at http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001280/, accessed July 15, 2011

(ii) PubMed Health, available at http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001467/, accessed July 15, 2011


'/>"/>
SOURCE HYCOR Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HYCOR Appoints Sean-Xavier Neath as Chief Medical Officer to Support Expansion of Product Lines and Enhance Customer Support Offerings
2. HYCOR Expands Board of Directors to Support Growth in Key Areas
3. InspireMD Broadens Global Distribution Network; Signs Distributor for the Russian Federation
4. United Spinal Association Broadens Its Reach with Users First: Giving Voice to All Wheelchair Users
5. GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling
6. Industry Leader BioStorage Technologies Broadens Sample Management Operations to Include Laboratory Sample Preparation Services
7. FDA Broadens Clearance for Agendias MammaPrint(R)
8. SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise
9. BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman
10. Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors
11. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... firsts,: , TwinLink™ - the first dual ...
Breaking Medicine Technology:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):